Pain Management

Astellas Pharma is a pharmaceutical company committed to discovering and developing new approaches to pain management.

Central to this effort is Astellas' rational drug discovery process. Through this process, we investigate the core mechanisms of pain in order to achieve our aim of discovering treatments with the potential to fulfil unmet medical needs and offer a brighter future for patients whose quality of life is compromised by chronic pain.

Our first area of focus is neuropathic pain. Neuropathic pain results from damage to nerves rather than to skin, muscle or bone.

The symptoms are often described as ‘burning’, ‘stabbing’ or ‘electric shock-like,’ and can include a variety of unpleasant and painful sensations. Exactly how many people suffer from neuropathic pain is not known but estimates for the percentage of the European population affected by the condition range from 3% to as high as 8%.1

1Giron et al. CMAJ 2006 / Mailis Gagnon A et al. European Journal of Pain 2007